Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia
Louise Geddes
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
Contribution: Data curation, Formal analysis, Investigation, Project administration
Search for more papers by this authorJenny Iversen
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
Contribution: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision
Search for more papers by this authorHandan Wand
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
Contribution: Formal analysis, Supervision
Search for more papers by this authorCorresponding Author
Lisa Maher
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
The Burnet Institute, Melbourne, VIC, Australia
Correspondence to: Lisa Maher, The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney NSW 2052, Australia. E-mail: [email protected]Contribution: Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision
Search for more papers by this authorLouise Geddes
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
Contribution: Data curation, Formal analysis, Investigation, Project administration
Search for more papers by this authorJenny Iversen
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
Contribution: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision
Search for more papers by this authorHandan Wand
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
Contribution: Formal analysis, Supervision
Search for more papers by this authorCorresponding Author
Lisa Maher
The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia
The Burnet Institute, Melbourne, VIC, Australia
Correspondence to: Lisa Maher, The Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney NSW 2052, Australia. E-mail: [email protected]Contribution: Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision
Search for more papers by this authorAbstract
Aims
To estimate incidence and predictors of opioid agonist therapy (OAT) discontinuation in a national cohort of people who inject drugs (PWID).
Design and Setting
Annually repeated cross-sectional serosurveillance among PWID attending ~50 needle–syringe programmes across Australia.
Participants
Between 1995 and 2018, 2651 PWID who reported current OAT and had subsequent survey participation completed 6739 surveys. Respondents were followed over 11 984 person-years of observation (PYO). Respondents were predominantly male (60%), and the median age was 34 years. Heroin was the most commonly reported drug last injected (46%), and methadone was the most commonly prescribed OAT (77%).
Measurements
The primary outcome was discontinuation of OAT (methadone, buprenorphine or buprenorphine–naloxone). Among respondents who reported current OAT, those who did not report current OAT in all subsequent records were defined as discontinued, and those with current OAT at all subsequent records were defined as retained. Predictors of discontinuation included self-reported demographic (sex, location, Indigenous status) and drug use characteristics (drug last injected, frequency of injection).
Findings
Just fewer than one-third of respondents (29%) reported an OAT discontinuation event. The crude discontinuation rate was 6.3 [95% confidence intervals (CI) = 5.9–6.8] per 100 PYO. Discontinuation was significantly higher among respondents who reported last injecting pharmaceutical opioids [adjusted hazard ratio (aHR) = 1.75, 95% CI = 1.41–2.17, P < 0.001], being prescribed buprenorphine (aHR = 1.44, 95% CI = 1.18–1.76, P = 0.001) or buprenorphine–naloxone (aHR = 1.68, 95% CI = 1.20–2.34, P = 0.002), daily or more frequent injection (aHR = 1.51, 95% CI = 1.23–1.85, P < 0.001), recent public injecting (aHR = 1.37, 95% CI = 1.17–1.60, P < 0.001), incarceration in the previous 12 months (aHR = 1.31, 95% CI = 1.05–1.64, P = 0.017), recent receptive syringe or injection equipment sharing (aHR = 1.28, 95% CI = 1.10–1.48, P = 0.001) and male sex (aHR = 1.27, 95% CI = 1.09–1.47, P = 0.002).
Conclusion
People who inject drugs attending needle–syringe programmes in Australia appear to be significantly more likely to discontinue opioid agonist treatment if they were prescribed buprenorphine or buprenorphine–naloxone compared with methadone, are male or report injection risk behaviours and recent incarceration.
References
- 1Schuckit M. A. Treatment of opioid-use disorders. N Engl J Med 2016; 375: 357–368.
- 2Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002209.
- 3Gowing L., Farrell M., Bornemann R., Sullivan L., Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; 2: CD004145.
- 4White B., Dore G. J., Lloyd A. R., Rawlinson W. D., Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-C study. Med J Aust 2014; 201: 326–329.
- 5Nolan S., Dias Lima V., Fairbairn N., Kerr T., Montaner J., Grebely J., et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014; 109: 2053–2059.
- 6MacArthur G. J., Minozzi S., Martin N., Vickerman P., Deren S., Bruneau J., et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 2012; 345: e5945.
- 7Platt L., Minozzi S., Reed J., Vickerman P., Hagan H., French C., et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis. Addiction 2018; 113: 545–563.
- 8Sordo L., Barrio G., Bravo M. J., Indave B. I., Degenhardt L., Wiessing L., et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357: j1550.
- 9Maglione M. A., Raaen L., Chen C., Azhar G., Shahidinia N., Shen M., et al. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. J Subst Abuse Treat 2018; 89: 28–51.
- 10Low A. J., Mburu G., Welton N. J., May M. T., Davies C. F., French C., et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis 2016; 63: 1094–1104.
- 11 Pharmaceutical Benefits Scheme. ‘Opiate Dependence Treatment Program’. Available at: https://www.pbs.gov.au/browse/section100-md (accessed 8 December 2019).
- 12 Australian Institute of Health Welfare (AIHW) National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018. Canberra: AIHW; 2019.
- 13Heard S., Iversen J., Geddes L., Maher L. Australian Needle Syringe Program Survey National Data Report 2014–2018: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney; 2019.
- 14Peacock A., Gibbs D., Sutherland R., Uporova J., Karlsson A., Bruno R., et al. Australian Drug Trends 2018. Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2018.
- 15Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3; CD002208.
- 16Shepherd A., Perrella B., Hattingh H. L. The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study. Subst Abuse Treat Prev Policy 2014; 9: 32.
- 17Lord S., Kelsall J., Kirwan A., King T. Opioid pharmacotherapy fees: a long-standing barrier to treatment entry and retention. Policy Brief 2014; 8: 1–4.
- 18Kourounis G., Richards B. D. W., Kyprianou E., Symeonidou E., Malliori M.-M., Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend 2016; 161: 1–8.
- 19Flynn P. M., Joe G. W., Broome K. M., Simpson D. D., Brown B. S. Recovery from opioid addiction in DATOS. J Subst Abuse Treat 2003; 25: 177–186.
- 20Weiss R. D., Potter J. S., Griffin M. L., Provost S. E., Fitzmaurice G. M., McDermott K. A., et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend 2015; 150: 112–119.
- 21Lawrinson P., Ali R., Buavirat A., Chiamwongpaet S., Dvoryak S., Habrat B., et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008; 103: 1484–1492.
- 22Burns L., Gisev N., Larney S., Dobbins T., Gibson A., Kimber J., et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015; 110: 646–655.
- 23MacDonald M. A., Wodak A. D., Dolan K. A., van Beek I., Cunningham P. H., Kaldor J. M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Med J Aust 2000; 172: 57–61.
- 24Iversen J., Wand H., Topp L., Kaldor J., Maher L. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health 2013; 103: 1436–1444.
- 25Topp L., Iversen J., Wand H., Day C., Kaldor J., Maher L. Programs CoANS. Representativeness of injecting drug users who participate in HIV surveillance: results from Australia's needle and syringe program survey. J Acquir Immune Defic Syndr 2008; 47: 632–638.
- 26Piasecki B. A., Lewis J. D., Rajender Reddy K., Bellamy S. L., Porter S. B., Weinrieb R. M., et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004; 40: 892–899.
- 27Grambsch P. M., Therneau T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.
- 28Cox D., Oakes D. Analysis of Survival Data. London, UK: Chapman and Hall; 1984.
- 29Cox D. R., Snell E. J. A general definition of residuals. J R Stat Soc B Methodol 1968; 30: 248–265.
- 30Barnett P., Rodgers J., Bloch D. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96: 683–690.
- 31Warden D., Subramaniam G. A., Carmody T., Woody G. E., Minhajuddin A., Poole S. A., et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav 2012; 37: 1046–1053.
- 32Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
- 33Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; 4: CD001333.
- 34Geddes L., Iversen J., Memedovic S., Maher L. Intravenous fentanyl use among people who inject drugs in Australia. Drug Alcohol Rev 2018; 37: S314–S322.
- 35Iversen J., Dertadian G., Geddes L., Maher L. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. Int J Drug Policy 2017; 42: 1–6.
- 36Lea T., Sheridan J., Winstock A. Consumer satisfaction with opioid treatment services at community pharmacies in Australia. Pharm World Sci 2008; 30: 940–946.
- 37Wakeman S. E., Rich J. D. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse 2018; 53: 330–333.
- 38Stöver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res 2011; 17: 44–54.
- 39 Royal Australian College of General Practitioners. Renewed calls to fully subsidise methadone treatment. Available at: https://www1.racgp.org.au/newsgp/clinical/renewed-calls-to-fully-subsidise-methadone-treatme (accessed 21 January 2020).
- 40Griffiths T. Review of Pharmacy Remuneration and Regulation Submission #262. Victorian Pharmacotherapy Area Based Networks 2016. Available at: https://www1.health.gov.au/internet/main/publishing.nsf/Content/review-pharmacy-remuneration-regulation-submissions-cnt-6/$file/262-2016-09-23-victorian-pharmacotherapy-area-based-networks-submission.pdf (accessed 21 January 2020)
- 41Saloner B., Stoller K. B., Barry C. L. Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment. Psychiatr Serv 2016; 67: 676–679.
- 42Deck D., Carlson M. J. Retention in publicly funded methadone maintenance treatment in two western states. J Behav Health Serv Res 2005; 32: 43–60.
- 43Bell J., Waal R. V. D., Strang J. Supervised injectable heroin: a clinical perspective. Can J Psychiatry 2017; 62: 451–456.
- 44Ferri M., Davoli M., Perucci C. A. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2010; 8: CD003410.
- 45Oviedo-Joekes E., Guh D., Brissette S., Marchand K., MacDonald S., Lock K., et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry 2016; 73: 447–455.
- 46Byford S., Barrett B., Metrebian N., Groshkova T., Cary M., Charles V., et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry 2013; 203: 341–349.
- 47Strang J., Groshkova T., Uchtenhagen A., van den Brink W., Haasen C., Schechter M. T., et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry 2015; 207: 5–14.
- 48Strang J., Metrebian N., Lintzeris N., Potts L., Carnwath T., Mayet S., et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 1885–1895.
- 49Fairbairn N., Ross J., Trew M., Meador K., Turnbull J., MacDonald S., et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. Can Med Assoc J 2019; 191: E1049–E1056.
- 50Belackova V., Salmon A. M., Jauncey M., Bell J. Learning from the past, looking to the future-is there a place for injectable opioid treatment among Australia's responses to opioid misuse? Int J Drug Policy 2019; 71: 164–168.
- 51Bell J., Belackova V., Lintzeris N. Supervised injectable opioid treatment for the management of opioid dependence. Drugs 2018; 78: 1339–1352.
- 52Larney S., Toson B., Burns L., Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction 2012; 107: 372–380.
- 53Visher C. A., Kachnowski V., La Vigne N. G., Travis J. Baltimore Prisoners’ Experiences Returning Home. Washington, DC: Urban Institute; 2004.
10.1037/e720322011-001 Google Scholar
- 54Iguchi M. Y., Bell J., Ramchand R. N., Fain T. How criminal system racial disparities may translate into health disparities. J Health Care Poor Underserv 2005; 16: 48–56.
- 55Mallik-Kane K., Visher C. A. Health and Prisoner Reentry: How Physical, Mental, and Substance Abuse Conditions Shape the Process of Reintegration. Washington, DC: Urban Institute Justice Policy Center; 2008.
- 56Degenhardt L., Larney S., Kimber J., Gisev N., Farrell M., Dobbins T., et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction 2014; 109: 1306–1317.
- 57Kelly S. M., O'Grady K. E., Mitchell S. G., Brown B. S., Schwartz R. P. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend 2011; 117: 170–175.
- 58Mullen L., Barry J., Long J., Keenan E., Mulholland D., Grogan L., et al. A national study of the retention of Irish opiate users in methadone substitution treatment. Am J Drug Alcohol Abuse 2012; 38: 551–558.
- 59Schofield T., Connell R. W., Walker L., Wood J. F., Butland D. L. Understanding men's health and illness: a gender-relations approach to policy, research, and practice. J Am Coll Health 2000; 48: 247–256.
- 60Geddes L., Iversen J., Wand H., Esmaeili A., Tsui J., Hellard M., et al. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. Clin Infect Dis 2019; 70: 123–131.
- 61Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253–263.
- 62Latkin C. A., Vlahov D., Anthony J. C. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993; 88: 517–526.
- 63White B., Day C., Maher L. Self reported risk behaviour among injecting drug users: self versus assisted questionnaire completion. AIDS Care 2007; 19: 441–447.
